A Canadian study of 2760 patients with asthma at 246 centers in 22 countries found that combining an inhaled corticosteroid and a long-lasting beta-2 agonist appeared to provide consistent relief for individuals with asthma. Specifically, there was a 45% lower exacerbation rate with the combined budenoside/formoterol therapy. The treatment also lowered overall severe exacerbation levels and delays in exacerbations requiring medical attention, improved lung function, reduced awakenings at night because of disease, and improved symptom control. (The findings were reported in the American Journal of Respiratory and Critical Care Medicine, January 2005).
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs